Faricimab increased treatment intervals and decreased CST in previously treated nAMD patients, but BCVA remained unchanged. The study included 88 eyes from 73 patients, with a mean follow-up of 30.1 ...
Please provide your email address to receive an email when new articles are posted on . Incidence rates for second through sixth cSCCs increased (28% to 67%), while time intervals decreased (1.4 to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback